ATE370932T1 - Ccr-3-rezeptorantagonisten vii - Google Patents

Ccr-3-rezeptorantagonisten vii

Info

Publication number
ATE370932T1
ATE370932T1 AT02803781T AT02803781T ATE370932T1 AT E370932 T1 ATE370932 T1 AT E370932T1 AT 02803781 T AT02803781 T AT 02803781T AT 02803781 T AT02803781 T AT 02803781T AT E370932 T1 ATE370932 T1 AT E370932T1
Authority
AT
Austria
Prior art keywords
ccr
vii
receptor antagonists
antagonists
receptor
Prior art date
Application number
AT02803781T
Other languages
English (en)
Inventor
Bois Daisy Du
Beihan Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE370932T1 publication Critical patent/ATE370932T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT02803781T 2001-11-30 2002-11-20 Ccr-3-rezeptorantagonisten vii ATE370932T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33481901P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
ATE370932T1 true ATE370932T1 (de) 2007-09-15

Family

ID=23308965

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02803781T ATE370932T1 (de) 2001-11-30 2002-11-20 Ccr-3-rezeptorantagonisten vii

Country Status (16)

Country Link
US (1) US7019007B2 (de)
EP (1) EP1453804B1 (de)
JP (1) JP2005518364A (de)
KR (1) KR100579352B1 (de)
CN (1) CN1296356C (de)
AR (1) AR037586A1 (de)
AT (1) ATE370932T1 (de)
AU (1) AU2002356694A1 (de)
BR (1) BR0214611A (de)
CA (1) CA2468402A1 (de)
DE (1) DE60222015T2 (de)
ES (1) ES2291539T3 (de)
MX (1) MXPA04004980A (de)
PL (1) PL373275A1 (de)
RU (1) RU2004120065A (de)
WO (1) WO2003045917A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002525A2 (en) * 2000-06-30 2002-01-10 Bristol-Myers Squibb Pharma Company N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
JP2006508948A (ja) * 2002-10-30 2006-03-16 メルク エンド カムパニー インコーポレーテッド ケモカイン受容体活性のヘテロアリールピペリジンモジュレーター
WO2004073634A2 (en) * 2003-02-20 2004-09-02 Encysive Pharmaceuticals Inc. Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists
EP1640361B9 (de) * 2003-06-30 2015-11-04 Sumitomo Chemical Company, Limited Asymmetrische harnstoff-verbindungen und verfahren zur herstellung von asymmetrischen verbindungen durch asymmetrische konjugat-additionsreaktion unter verwendung dieser verbindungen als katalysator
US7541468B2 (en) * 2004-06-10 2009-06-02 Bristol-Myers Squibb Company Process of preparing N-ureidoalkyl-piperidines
ES2624845T3 (es) * 2010-09-29 2017-07-17 Intervet International B.V. Compuestos de N-heteroarilo con unidad de puente cíclico para el tratamiento de enfermedades parasitarias

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB953005A (en) * 1961-02-24 1964-03-18 Soc Ind Fab Antibiotiques Sifa Substituted n-phenylethyl-n-phenyl-piperazines
US5051423A (en) 1988-07-13 1991-09-24 Schering Ag Derivatized alkanolamines as cardiovascular agents
HU206337B (en) * 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
JPH0592921A (ja) * 1991-05-17 1993-04-16 Yamanouchi Pharmaceut Co Ltd シクロヘキシルアルキルアミド および 該化合物を有効成分とするタキキニン抑制剤
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
DE69829875T2 (de) * 1997-10-14 2006-03-09 Mitsubishi Pharma Corp. Piperazin-verbindungen und ihre medizinische verwendung
US6331541B1 (en) * 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU3126700A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2482100A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2057200A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2347909A1 (en) 1998-12-18 2000-06-22 Joseph B. Santella, Iii N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
HK1044282A1 (zh) * 1998-12-18 2002-10-18 Bristol-Myers Squibb Pharma Company 作为趋化因子受体活性调节剂的n-脲基烷基-哌啶化合物
WO2001007427A1 (en) * 1999-07-28 2001-02-01 Daiichi Radioisotope Laboratories, Ltd. Vesamicol piperazine derivatives and drugs containing the same
GB0012240D0 (en) * 2000-05-19 2000-07-12 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
ES2291539T3 (es) 2008-03-01
DE60222015D1 (de) 2007-10-04
BR0214611A (pt) 2004-09-14
US20030153578A1 (en) 2003-08-14
WO2003045917A3 (en) 2003-10-09
JP2005518364A (ja) 2005-06-23
EP1453804A2 (de) 2004-09-08
KR20040062663A (ko) 2004-07-07
WO2003045917A2 (en) 2003-06-05
CN1599721A (zh) 2005-03-23
AU2002356694A1 (en) 2003-06-10
RU2004120065A (ru) 2005-05-27
KR100579352B1 (ko) 2006-05-12
PL373275A1 (en) 2005-08-22
EP1453804B1 (de) 2007-08-22
CN1296356C (zh) 2007-01-24
US7019007B2 (en) 2006-03-28
MXPA04004980A (es) 2004-08-11
DE60222015T2 (de) 2008-06-05
AR037586A1 (es) 2004-11-17
WO2003045917B1 (en) 2003-12-04
CA2468402A1 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
ATE368659T1 (de) Thrombinrezeptorantagonisten
ATE346043T1 (de) Il-8-rezeptorantagonisten
NO20025754D0 (no) IL-8 Reseptor-antagonister
DE60136562D1 (de) Heteroaryl-harnstoff-neuropeptid-y-y5-rezeptor-antagonisten
DE60112051D1 (de) Il-8 rezeptor antagonisten
DK1261336T3 (da) IL-8-receptorantagonister
ATE374183T1 (de) Nk1-antagonisten
DE60130000D1 (de) Zwitterionische tachykinin-rezeptor-antagonisten
NO20016052D0 (no) IL-8-reseptor-antagonister
MA25739A1 (fr) Antagonistes recepteurs il-8
DK1372688T3 (da) Somatostatin-antagonister
DK1180028T3 (da) IL-8-receptorantagonister
DE60222015D1 (de) Ccr-3-rezeptorantagonisten vii
NO20024367D0 (no) IL-8 reseptorantagonister
NO20015774D0 (no) IL-8 reseptorantagonister
NO20033223D0 (no) Histamin-reseptor antagonister
PL370367A1 (en) Ccr-3 receptor antagonists v
DE60134427D1 (de) Exzitatorische aminosäure-rezeptor-antagonisten
ATE320254T1 (de) Crf receptor antagonisten
NO20024366L (no) IL-8 reseptorantagonister
SE0003996D0 (sv) Receptorantagonister
DK1131291T3 (da) 4-aroyl-piperidin-CCR-3-receptorantagonister III

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties